Anthelmintic cyclcooctadepsipeptides: Complex in structure and mode of action

Trends in Parasitology

Volumn 28, Issue 9, 2012, Pages 385-394

  Krücken, Jürgen ^a   Harder, Achim ^b   Jeschke, Peter ^c   Holden Dye, Lindy ^d   O'Connor, Vincent ^d   Welz, Claudia ^e   Von Samson Himmelstjerna, Georg ^a  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c BAYER CROPSCIENCE AG   (Germany)

^d UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^e BAYER AG   (Germany)

Author keywords

Anthelmintic cyclcooctadepsipeptides; Emodepside; Lathrophilin; PF1022A; PF1022A synthesis; Rosellinia; SLO 1

Indexed keywords

CYCLCOOCTADEPSIPEPTIDE PF1022A; CYCLODEPSIPEPTIDE; EMODEPSIDE; UNCLASSIFIED DRUG;

ANTHELMINTIC ACTIVITY; DRUG MECHANISM; DRUG STRUCTURE; DRUG SYNTHESIS; NEMATODE; NEUROMUSCULAR FUNCTION; NONHUMAN; NUCLEOTIDE SEQUENCE; REVIEW; STRUCTURE ACTIVITY RELATION;

CAMELLIA JAPONICA; MYCELIA STERILIA; ROSELLINIA;

EID: 84865187698     PISSN: 14714922     EISSN: 14715007     Source Type: Journal    
DOI: 10.1016/j.pt.2012.06.005     Document Type: Review

References (102)

1. Harder A. Chemotherapeutic approaches to nematodes: current knowledge and outlook. Parasitol. Res. 2002, 88:272-277.
2. Encyclopedic Reference of Parasitology 2007, Springer. H. Mehlhorn (Ed.).
3. Martin R.J., Robertson A.P. Mode of action of levamisole and pyrantel, anthelmintic resistance, E153 and Q57. Parasitology 2007, 134:1093-1104.
4. Rufener L., et al. Monepantel allosterically activates DEG-3/DES-2 channels of the gastrointestinal nematode Haemonchus contortus. Mol. Pharmacol. 2010, 78:895-902.
5. Kaminsky R., et al. A new class of anthelmintics effective against drug-resistant nematodes. Nature 2008, 452:176-180.
6. Keiser J., Utzinger J. Efficacy of current drugs against soil-transmitted helminth infections: systematic review and meta-analysis. JAMA 2008, 299:1937-1948.
7. Crump A., Otoguro K. Satoshi Omura: in pursuit of nature's bounty. Trends Parasitol. 2005, 21:126-132.
8. Geary T.G., Mackenzie C.D. Progress and challenges in the discovery of macrofilaricidal drugs. Expert Rev. Anti Infect. Ther. 2011, 9:681-695.
9. Little P.R., et al. Field efficacy and safety of an oral formulation of the novel combination anthelmintic, derquantel-abamectin, in sheep in New Zealand. N. Z. Vet. J. 2010, 58:121-129.
10. Wolstenholme A.J., et al. Drug resistance in veterinary helminths. Trends Parasitol. 2004, 20:469-476.
11. Demeler J., et al. Monitoring the efficacy of ivermectin and albendazole against gastro intestinal nematodes of cattle in Northern Europe. Vet. Parasitol. 2009, 160:109-115.
12. Kaplan R.M. Anthelmintic resistance in nematodes of horses. Vet. Res. 2002, 33:491-507.
13. von Samson-Himmelstjerna G., et al. Cases of reduced cyathostomin egg-reappearance period and failure of Parascaris equorum egg count reduction following ivermectin treatment as well as survey on pyrantel efficacy on German horse farms. Vet. Parasitol. 2007, 144:74-80.
14. Sasaki T., et al. A new anthelmintic cyclodepsipeptide, PF1022A. J. Antibiot. (Tokyo) 1992, 45:692-697.
15. Miyadoh S., et al. Taxonomic position of the fungus producing the anthelmintic PF1022 based on the 18S rRNA gene base sequence. Nippon Kingakukai Kaiho 2000, 41:183-188.
16. Ohyama, M. et al. Meiji Seika Kaisha, Ltd., Japan. Process for producing cyclodepsipeptide compounds with microorganisms, PCT Int. Appl., WO 9805655 A1 19980212, ref. CAN 128:179454.
17. Suzuki A., et al. Bassianolide - new insecticidal cyclodepsipeptide from Beauveria bassiana and Verticillium lecanii. Tetrahedron Lett. 1977, 18:2167-2170.
18. Amliwala K., et al. Emodepside, a cyclo-octadepsipeptide anthelmintic with a novel mode of action. Drugs Future 2004, 29:1015-1024.
19. Harder A., et al. Cyclooctadepsipeptides - an anthelmintically active class of compounds exhibiting a novel mode of action. Antiparasitic and Antibacterial Drug Discovery: From Molecular Targets to Drug Candidates 2009, 339-356. Wiley-VCH. P.M. Selzer (Ed.).
20. Harder A., et al. Cyclooctadepsipeptides - an anthelmintically active class of compounds exhibiting a novel mode of action. Int. J. Antimicrob. Agents 2003, 22:318-331.
21. Scherkenbeck J., et al. PF1022A and related cyclodepsipeptides - a novel class of anthelmintics. Curr. Top. Med. Chem. 2002, 2:759-777.
22. Nishiyama, H. et al. (1993) Fujisawa Pharmaceutical Co., Ltd., Japan. Preparation of depsipeptides derivatives as anthelmintics. PCT Int. Appl., 118 pp. WO 9319053 A1 19930930; ref. CAN 121:134806.
23. Müller J., et al. In vitro synthesis of new cyclodepsipeptides of the PF1022-type: probing the α-D-hydroxy acid tolerance of PH1022 synthetase. Chembiochem 2009, 10:323-328.
24. Weckwerth W., et al. Biosynthesis of PF1022A and related cyclooctadepsipeptides. J. Biol. Chem. 2000, 275:17909-17915.
25. Weber G., et al. The peptide synthetase catalyzing cyclosporine production in Tolypocladium niveum is encoded by a giant 45.8-kilobase open reading frame. Curr. Genet. 1994, 26:120-125.
26. Yanai K., et al. Para-position derivatives of fungal anthelmintic cyclodepsipeptides engineered with Streptomyces venezuelae antibiotic biosynthetic genes. Nat. Biotechnol. 2004, 22:848-855.
27. Terada M. Neuropharmacological mechanism of action of PF1022A, an antinematode anthelmintic with a new structure of cyclic depsipeptide, on Angiostrongylus cantonensis and isolated frog rectus. Jpn. J. Parasitol. 1992, 41:108-117.
28. Kachi S., et al. Effects of amorphous and polymorphs of PF1022A, a new antinematode drug, on Angiostrongylus costaricensis in mice. Jpn. J. Parasitol. 1998, 77:235-245.
29. Martin R.J., et al. Anthelmintic actions of the cyclic depsipeptide PF1022A and its electrophysiological effects on muscle cells of Ascaris suum. Pestic. Sci. 1996, 48:343-349.
30. Terada M., et al. Effects of PF1022A on developing larvae of Angiostrongylus costaricensis in mice, with special reference to route, dose and formulation. Jpn. J. Parasitol. 1993, 42:199-210.
31. Akyol C.V., et al. Effects of PF1022A, a newly developed gabergic anthelmintic, on adult stage of Angiostrongylus cantonensis in rats. Jpn. J. Parasitol. 1993, 42:220-226.
32. Kachi S., et al. Effects of PF1022A on Angiostrongylus cantonensis staying in the central nervous system of rats and mice. Jpn. J. Parasitol. 1994, 43:483-488.
33. Kachi S., et al. Effects of PF1022A on adult Angiostrongylus cantonensis in the pulmonary arteries and larvae migration into the central nervous system of rats. Parasitol. Res. 1995, 81:631-637.
34. Bernt U., et al. Effects of anthelmintics with different modes of action on the behavior and development of Caenorhabditis elegans. Fundam. Appl. Nematol. 1998, 21:251-263.
35. Harder A., von Samson-Himmelstjerna G. Activity of the cyclic depsipeptide emodepside (BAY 44-4400) against larval and adult stages of nematodes in rodents and the influence on worm survival. Parasitol. Res. 2001, 87:924-928.
36. Nicolay F., et al. Synergistic action of BAY 44-4400 and piperazine on nematodes of the mouse in-vitro and in-vivo: a light and transmission electron microscopic study. Parasitol. Res. 2000, 86:982-992.
37. Schmahl G., et al. Efficacy of a combination of emodepside plus praziquantel against larval and adult stages of nematodes (Trichuris muris, Angiostrongylus cantonensis) in rodents. Parasitol. Res. 2007, 101:S77-S84.
38. Conder G.A., et al. Anthelmintic profile of the cyclodepsipeptide PF1022A in in-vitro and in-vivo models. J. Antibiot. 1995, 48:820-823.
39. Mehlhorn H., et al. Effects of a combination of emodepside and praziquantel on parasites of reptiles and rodents. Parasitol. Res. 2005, 97(Suppl. 1):S65-S69.
40. Altreuther G., et al. Efficacy of a topically administered combination of emodepside and praziquantel against mature and immature Ancylostoma tubaeforme in domestic cats. Parasitol. Res. 2005, 97(Suppl. 1):S51-S57.
41. Altreuther G., et al. Field evaluation of the efficacy and safety of emodepside/praziquantel spot-on solution against naturally acquired nematode and cestode infections in domestic cats. Parasitol. Res. 2005, 97(Suppl. 1):S58-S64.
42. ® oral suspension for dogs) against naturally acquired nematode and Isospora spp. infections in dogs. Parasitol. Res. 2011, 109(Suppl. 1):S21-S28.
43. ® oral suspension for dogs) against prepatent and patent infection with Isospora canis and Isospora ohioensis-complex in dogs. Parasitol. Res. 2011, 109(Suppl. 1):S9-S20.
44. Fukashe, T. et al. (1990) Anthelmintic effects of PF1022, a new cyclic depsipeptide, on the intestinal nematodes in dogs and cats. Proceedings of the 110th Meeting of the Japanese Soc. Vet. Science, p. 122.
45. Reinemeyer C.R., et al. Evaluation of the efficacy of emodepside plus praziquantel topical solution against ascarid infections (Toxocara cati or Toxascaris leonina) in cats. Parasitol. Res. 2005, 97(Suppl. 1):S41-S50.
46. ® oral suspension for dogs (0.1% emodepside and 2% toltrazuril) against experimental nematode (Toxocara cati and Ancylostoma tubaeforme) infections in cats. Parasitol. Res. 2011, 109(Suppl. 1):S37-S43.
47. ® oral suspension for dogs) against mixed experimental Isospora felis/Isospora rivolta infection in cats. Parasitol. Res. 2011, 109(Suppl. 1):S29-S36.
48. Schaper R., et al. Efficacy of emodepside plus praziquantel topical solution against immature stages of nematodes (Ancylostoma sp. and Toxocara sp.) in cats. Parasitol. Res. 2007, 101:S63-S68.
49. ® oral suspension for dogs) against Toxocara canis, Uncinaria stenocephala and Ancylostoma caninum in dogs. Parasitol. Res. 2011, 109(Suppl. 1):S1-S8.
50. von Samson-Himmelstjerna G., et al. In vivo activities of the new anthelmintic depsipeptide PF1022A. Parasitol. Res. 2000, 86:194-199.
51. von Samson-Himmelstjerna G., et al. Efficacy of two cyclooctadepsipeptides, PF1022A and emodepside, against anthelmintic-resistant nematodes in sheep and cattle. Parasitology 2005, 130:343-347.
52. Zahner H., et al. Effects of Bay 44-4400, a new cyclodepsipeptide, on developing stages of filariae (Acanthocheilonema viteae, Brugia malayi, Litomosoides sigmodontis) in the rodent Mastomys coucha. Acta Trop. 2001, 80:19-28.
53. Zahner H., et al. Filaricidal efficacy of anthelmintically active cyclodepsipeptides. Int. J. Parasitol. 2001, 31:1515-1522.
54. Gessner G., et al. Ionophorous and anthelmintic activity of PF1022A, a cyclooctadepsipeptide, are not related. Pestic. Sci. 1996, 48:399-407.
55. Willson J., et al. The effect of the anthelmintic emodepside at the neuromuscular junction of the parasitic nematode Ascaris suum. Parasitology 2003, 126:79-86.
56. Willson J., et al. A possible mechanism for the action of the novel anthelmintic emodepside, using Ascaris suum body wall muscle preparations. J. Physiol. 2001, 536:132-133.
57. Chen W., et al. Characterization of subtypes of γ-aminobutyric acid receptors in an Ascaris muscle preparation by binding assay and binding of PF1022A, a new anthelmintic, on the receptors. Parasitol. Res. 1996, 82:97-101.
58. Holden-Dye L., et al. Studies involving avermectin and the 4-aminobutyric acid (GABA) receptor of Ascaris suum muscle. Pest Manag. Sci. 1988, 24:231-245.
59. 3H-methyl) PF1022A. J. Labelled Comp. Rad. 1995, 38:61-69.
60. Richmond J.E., Jorgensen E.M. One GABA and two acetylcholine receptors function at the C. elegans neuromuscular junction. Nat. Neurosci. 1999, 2:791-797.
61. Bamber B.A., et al. The Caenorhabditis elegans unc-49 locus encodes multiple subunits of a heteromultimeric GABA receptor. J. Neurosci. 1999, 19:5348-5359.
62. Bamber B.A., et al. The composition of the GABA receptor at the Caenorhabditis elegans neuromuscular junction. Br. J. Pharmacol. 2005, 144:502-509.
63. Miltsch S.M., et al. Decreased emodepside sensitivity in unc-49 γ-aminobutyric acid (GABA)-receptor-deficient Caenorhabditis elegans. Int. J. Parasitol. 2012, 42:761-770.
64. Saeger B., et al. Latrophilin-like receptor from the parasitic nematode Haemonchus contortus as target for the anthelmintic depsipeptide PF1022A. FASEB J. 2001, 15:1332-1334.
65. O'Sullivan M.L., et al. FLRT proteins are endogenous latrophilin ligands and regulate excitatory synapse development. Neuron 2012, 73:903-910.
66. Silva J.P., et al. Latrophilin 1 and its endogenous ligand Lasso/teneurin-2 form a high-affinity transsynaptic receptor pair with signaling capabilities. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:12113-12118.
67. Boucard A.A., et al. High affinity neurexin binding to cell adhesion G-protein-coupled receptor CIRL1/latrophilin-1 produces an intercellular adhesion complex. J. Biol. Chem. 2012, 287:9399-9413.
68. Krüger N., et al. The putative cyclooctadepsipeptide receptor depsiphilin of the canine hookworm Ancylostoma caninum. Parasitol. Res. 2009, 105(Suppl 1):91-100.
69. Welz C., et al. Putative G protein-coupled receptors in parasitic nematodes - potential targets for the new anthelmintic class cyclooctadepsipeptides?. Parasitol. Res. 2005, 97(Suppl. 1):S22-S32.
70. Mee C.J., et al. Latrophilin is required for toxicity of black widow spider venom in Caenorhabditis elegans. Biochem. J. 2004, 378:185-191.
71. Guest M., et al. The calcium-activated potassium channel, SLO-1, is required for the action of the novel cyclo-octadepsipeptide anthelmintic, emodepside, in Caenorhabditis elegans. Int. J. Parasitol. 2007, 37:1577-1588.
72. Willson J., et al. Latrotoxin receptor signaling engages the UNC-13-dependent vesicle-priming pathway in C. elegans. Curr. Biol. 2004, 14:1374-1379.
73. McVeigh P., et al. The FLP-side of nematodes. Trends Parasitol. 2006, 22:385-396.
74. Mühlfeld S., et al. FMRFamide-like neuropeptides as putative ligands of the latrophilin-like HC110-R from Haemonchus contortus. Mol. Biochem. Parasitol. 2009, 164:162-164.
75. Bull K., et al. Effects of the novel anthelmintic emodepside on the locomotion, egg-laying behaviour and development of Caenorhabditis elegans. Int. J. Parasitol. 2007, 37:627-636.
76. Amliwala, K. (2005) Molecular and genetic determinants of the inhibitory action of emodepside on C. elegans muscle, Division of Cell Sciences 2005, University of Southampton PhD Thesis: Southampton.
77. Welz C., et al. SLO-1-channels of parasitic nematodes reconstitute locomotor behaviour and emodepside sensitivity in Caenorhabditis elegans slo-1 loss of function mutants. PLoS Pathog. 2011, 7:e1001330.
78. Crisford A., et al. Selective toxicity of the anthelmintic emodepside revealed by heterologous expression of human KCNMA1 in Caenorhabditis elegans. Mol. Pharmacol. 2011, 79:1031-1043.
79. Buxton S.K., et al. On the mode of action of emodepside: slow effects on membrane potential and voltage-activated currents in Ascaris suum. Br. J. Pharmacol. 2011, 164:453-470.
80. Widmer H.A., et al. Conditional protein phosphorylation regulates BK channel activity in rat cerebellar Purkinje neurons. J. Physiol. 2003, 552:379-391.
81. 2+ channels via latrophilin in beta-cells. J. Biol. Chem. 2006, 281:5522-5531.
82. Holden-Dye L., et al. Worms take to the slo lane: a perspective on the mode of action of emodepside. Invert. Neurosci. 2012, 12:29-36.
83. Holden-Dye L., et al. SLO, SLO, quick, quick, slow: calcium-activated potassium channels as regulators of Caenorhabditis elegans behaviour and targets for anthelmintics. Invert. Neurosci. 2007, 7:199-208.
84. McKellar Q.A., Jackson F. Veterinary anthelmintics: old and new. Trends Parasitol. 2004, 20:456-461.
85. Lacey E. The role of the cytoskeletal protein, tubulin, in the mode of action and mechanism of drug resistance to benzimidazoles. Int. J. Parasitol. 1988, 18:885-936.
86. Martin R.J. Modes of action of anthelmintic drugs. Vet. J. 1997, 154:11-34.
87. Morton D.B., et al. Soluble guanylyl cyclases in Caenorhabditis elegans: NO is not the answer. Curr. Biol. 1999, 9:R546-R547.
88. Dutton F.E., Nelson S.J. Synthesis of PF1022A, an anthelmintic cyclodepsipeptide. J. Antibiot. (Tokyo) 1994, 47:1322-1327.
89. Kobayashi M., et al. Synthesis and anthelmintic activity of the cyclodepsipeptide, PF1022A. Sankyo Kenkyusho Nenpo 1994, 46:67-75.
90. Lee B.H. Solid-phase synthesis of cyclooctadepsipeptide PF1022A analogs using a cyclization-cleavage method with oxime resin. Tetrahedron Lett. 1997, 38:757-760.
91. Ohyama M., et al. Total synthesis of the anthelmintic cyclodepsipeptide PF1022A. Biosci. Biotechnol. Biochem. 1994, 58:1193-1194.
92. Scherkenbeck J., et al. A highly efficient synthesis of the anthelmintic cyclooctadepsipeptide PF1022A. Tetrahedron 1995, 51:8459-8470.
93. Ohyama M., et al. Chemistry of anthelmintic cyclodepsipeptides. Sci. Rep. Meiji Seika Kaisha 2006, 45:8-31.
94. Scherkenbeck J., et al. PF1022A - a novel anthelmintic cyclooctadepsipeptide. Modification and exchange of the N-methyl leucine residues. Bioorg. Med. Chem. Lett. 1998, 8:1035-1040.
95. Jeschke P., et al. Synthesis and anthelmintic activity of thioamide analogues of cyclic octadepsipeptides such as PF1022A. Pest Manag. Sci. 2001, 57:1000-1006.
96. Jeschke P., et al. Synthesis of anthelmintically active N-methylated amidoxime analogues of the cyclic octadepsipeptide PF1022A. Pest Manag. Sci. 2002, 58:1205-1215.
97. Dyker, H. et al. (1998) Bayer AG. Desoxycyclodepsipeptides and their use for combating endoparasites, WO 98/55469 A1.
98. Dyker H., et al. Azadepsipeptides: synthesis and evaluation of a novel class of peptidomimetics. J. Org. Chem. 2001, 66:3760-3766.
99. Scherkenbeck J., et al. Synthesis, conformational studies and anthelmintic activity of constrained PF1022A analogue. Pestic. Sci. 1999, 55:457-461.
100. Dutton F.E., Lee B.H. Epsilon-lactam analogs of the anthelmintic cyclodepsipeptide PF1022A. Tetrahedron Lett. 1998, 39:5313-5316.
101. Dyker H., et al. Chimeric cyclodepsipeptides as mimetics for the anthelmintic PF1022A. Bioorg. Med. Chem. Lett. 2004, 14:6129-6132.
102. Jeschke R., et al. Influence of the cyclooctadepsipeptides PF1022A and PF1022E as natural products on the design of semi-synthetic anthelmintics such as emodepside. Parasitol. Res. 2005, 97(Suppl. 1):S11-S16.